

Cytene expands in Asian market with subsidiary in Taiwan

24 July 2019 | News

Cytene Bioprocess Solutions will focus on providing bioprocess solutions for pharmaceutical companies and leading research institutes



Germany based Cytene, the specialist for single-cell technologies, is continuing its growth with the establishment of its subsidiary Cytene Bioprocess Solutions in Taiwan. Cytene Bioprocess Solutions is developing an innovative technology, which enables considerable reductions in time and increases in efficiency for cell line development.

"With the new R&D focused company, we want to further strengthen our global market position and open up new application areas and target markets. Our team in Taipei will enable us to be even closer to our Asian partners and use local R&D and production resources," says Dr. Jonas Schoendube, CEO of Cytene in Germany.

Cytene Bioprocess Solutions will focus on providing bioprocess solutions for pharmaceutical companies and leading research institutes. These solutions are based on an innovative microbioreactor called C.Bird. The C.Bird is the first microbioreactor to combine early stage cell culture screening, monitoring and optimization. This enables customers to save several weeks of cell line development by selecting the right clones or cell cultures very early in the process.

Jonas Schoendube is particularly pleased about the strong team on-site in Taiwan: "With Dr. Charles Tsai, CEO of Cytene Bioprocess Solutions, and Elbert Chen, CFO of Cytene Bioprocess Solutions, we have found partners who will use their expertise to drive the company forward."

"It is fantastic to be working with Cytene to bring to market a new leading-edge technology for cell line development. By establishing a site in Asia, Cytene will build new connections and enable fast delivery of our products to our global customers," says Charles Tsai.